MABVAX THERAPEUTICS HOLDINGS, INC. (NASDAQ:MBVX) Files An 8-K Regulation FD Disclosure
ITEM 7.01
REGULATION FD DISCLOSURE.
On June 27, 2017, MabVax Therapeutics Holdings, Inc. (the
Company) issued a press release announcing the first patient has
been dosed in the Phase 1 clinical trial evaluating MVT-1075, the
Companys fully human antibody radioimmunotherapy (RIT), for the
treatment of CA19-9 positive malignances including pancreatic,
colon and lung cancers. The press release is attached hereto as
Exhibit 99.1.
Company) issued a press release announcing the first patient has
been dosed in the Phase 1 clinical trial evaluating MVT-1075, the
Companys fully human antibody radioimmunotherapy (RIT), for the
treatment of CA19-9 positive malignances including pancreatic,
colon and lung cancers. The press release is attached hereto as
Exhibit 99.1.
The information disclosed under this Item 7.01, including Exhibit
99.1 hereto, is being furnished and shall not be deemed filed for
purposes of Section 18 of the Securities Exchange Act of 1934, as
amended, nor shall it be incorporated by reference into any
registration statement or other document to the Securities Act of
1933, as amended, except as expressly set forth in such filing.
99.1 hereto, is being furnished and shall not be deemed filed for
purposes of Section 18 of the Securities Exchange Act of 1934, as
amended, nor shall it be incorporated by reference into any
registration statement or other document to the Securities Act of
1933, as amended, except as expressly set forth in such filing.
ITEM 9.01
FINANCIAL STATEMENTS AND EXHIBITS
(d)Exhibits.
The exhibit listed in the following Exhibit Index is furnished
with this Current Report on Form 8-K.
with this Current Report on Form 8-K.
Exhibit No.
|
Description
|
|
99.1
|
Press Release dated June 27, 2017
|
MABVAX THERAPEUTICS HOLDINGS, INC. ExhibitEX-99.1 2 ex99-1.htm PRESS RELEASE Blueprint Exhibit 99.1 MabVax Therapeutics Commences Patient Dosing in MVT-1075 Radioimmunotherapy Phase 1 Clinical Trial for the Treatment of Pancreatic,…To view the full exhibit click here